Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women 18 years of age or older
Absence of contraindication to treatment with Zometa: creatinine clearance greater than 30 mL/min (with Cockroft or MDRD method).
Breast cancer (TNM IIa, IIb, IIIa) larger than 2cm in maximal diameter able to benefit from neoadjuvant chemotherapy
Ductal or lobular histological type of the breast tumor
WHO performance status 0-2
Patient who understands the french language
Covered by, or having the right to Social Security
Signed informed consent
You may not be if
Breast cancers of rare histological type (other than ductal and lobular)
Noninvasive cancer
Multifocal tumor (more than 2 tumoral lesions or 2 tumoral lesions distant more than 2cm each other)
T4 breast tumor
Presence of organ, bone, or skin metastases (in the initial staging workup)
Patient with a history of breast cancer
Other cancer currently in treatment (except carcinoma in situ).
Severe systemic disease potentially interfering with follow-up.
Contraindication to injected products: known allergy to bisphosphonates, zoledronic acid or excipients, severe renal failure (creatinine clearance \< 30 mL/min with Cockroft or MDRD method).
Women who are pregnant (positive pregnancy test) or breast-feeding, or absence of contraception in a woman who is able to become pregnant.
Patient with evolutionary dental problems, including dental infection or infection of the jaw,intrabuccal exposure of jawbone, and history or current diagnosis of osteonecrosis of the jaw,requiring a fast chirurgical care.
Prior treatment with bisphosphonates (either IV or oral).
History of severe bone disease (severe osteoporosis with multiple skeletal-related events).
Clareo Health | Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers
